| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Preoperative ctDNA and tumor volume predict colorectal cancer recurrence after metastasis resection. |
| 掲載誌名 | 正式名：NPJ precision oncology 略 称：NPJ Precis Oncol ISSNコード：2397768X/2397768X |
| 掲載区分 | 国外 |
| 巻・号・頁 | pp.Online ahead of print |
| 著者・共著者 | Hidekazu Oyoshi, Hideaki Bando, Riu Yamashita, Shun-Ichiro Kageyama, Yoshiaki Nakamura, Satoshi Horasawa, Masaki Nakamura, Takeshi Fujisawa, Kento Tomizawa, Atsushi Motegi, Hidehiro Hojo, Hidenari Hirata, Hiroki Yukami, Saori Mishima, Daisuke Kotani, Masaaki Miyo, Koji Ando, Jun Watanabe, Naoya Akazawa, Kozo Kataoka, Hiroya Taniguchi, Eiji Oki, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Adham Jurdi, Minetta C Liu, Toshihiro Misumi, Sadatomo Zenda, Takayuki Yoshino |
| 発行年月 | 2026/04 |
| 概要 | Circulating tumor DNA (ctDNA) testing in patients with colorectal cancer (CRC) has demonstrated clinical significance in various contexts, including post-curative resection. Therefore, we developed a predictive model integrating preoperative ctDNA levels with radiographic imaging to assess the risk of postoperative recurrence in patients with CRC. Patients with CRC from the GALAXY study with either newly diagnosed or recurrent, curatively resectable liver or lung metastases were enrolled between May 2020 and December 2022, and radiographic images were collected between February 2023 and January 2025. The ratio of preoperative ctDNA levels to tumor metastasis volume from radiographic imaging, ctDNA levels alone, and tumor volume alone was assessed. Overall, 181 and 48 patients from the GALAXY trial had liver and lung metastases, respectively. Among patients with liver metastases, the median progression-free survival (PFS) was 11.4 and 24 months in the high- and low-risk groups classified by the ctDNA model, respectively. Among patients with lung metastases, the median PFS was 12 months and not reached in the high- and low-risk groups classified by the ctDNA/volume model, respectively. Conclusively, incorporating radiological markers of necrosis and refining the tumor volume estimation may further improve model accuracy in liver metastasis settings. |
| DOI | 10.1038/s41698-026-01450-w |
| PMID | 42062528 |